I am a dedicated and detail-oriented engineer with extensive experience in process engineering, upstream process development, and process analytics. My career reflects a commitment to advancing cutting-edge gene therapy platforms, with expertise in upstream process engineering and cross-functional collaboration.At BE Biopharma, I contributed significantly to the development and optimization of novel B cell-based therapies. On the AAV core team, I worked cross functionally with research teams and stakeholders to drive timelines for various vector screenings to support multiple programs. Acting as subject matter expert (SME) for AAV production, I have experience in end-to-end production of viral vectors. My work on the analytical team involved designing and analyzing immunophenotyping panels, developing innovative gating strategies, and streamlining data analysis workflows to support IND enabling studies. I took pride in presenting findings to drive collaboration between teams and ensuring operational efficiency by managing critical lab resources.During my time at CRISPR Therapeutics, I played a pivotal role in advancing AAV production technologies and scaling processes from development to GMP readiness. As an Upstream Engineer, I optimized AAV manufacturing processes using suspension HEK293 cells, executing critical process steps such as vial thaw, triple transient transfection, production bioreactors, and harvest. I acted as the Person-in-Plant (PiP) for the generation of master cell banks, ensuring readiness for GMP-scale operations and collaborating with CMOs for tech transfer.In this role, I leveraged tools like JMP and DoE to design experiments that de-risked cell banks and characterized upstream processes. My work supported multiple campaigns, enabling consistent delivery of high-quality material. Additionally, I conducted flow cytometry analytics, including %CAR assays, to ensure process quality and performance.My ability to translate complex data into actionable insights and author detailed documentation such as SOPs, DOPs, and DBRs further supported the standardization and efficiency of operations. These experiences have enhanced my expertise in bioprocessing and gene therapy development while strengthening my ability to collaborate across cross-functional teams. By working closely with colleagues and partners, I have honed my skills in driving innovation and delivering impactful solutions to address complex challenges in the biopharma space.
